Acetylcholine receptor antibody (AChR antibody)

Acetylcholine receptor antibody refers to autoantibodies directed against the acetylcholine receptor, most commonly at the neuromuscular junction. These antibodies are not a molecular drug target themselves, but rather are biomarkers of autoimmune activity and disease—in particular, myasthenia gravis. They impede neuromuscular transmission by binding to, blocking, or modulating the acetylcholine receptor, ultimately leading to muscle weakness and fatigue. While they have diagnostic utility (multiple subtypes including binding, blocking, and modulating antibodies can be measured in patient serum), they are not the same as the acetylcholine receptor itself, which is a legitimate molecular target and ion channel. As such, "acetylcholine receptor antibody" is not a therapeutic target in the classical sense (like a receptor or enzyme), but rather a pathogenic biomarker that reflects an underlying autoimmune process. Key clarification: - "Acetylcholine receptor antibody" is not a canonical drug target; the correct therapeutic target in this context would be the **acetylcholine receptor (AChR)** itself (specifically, the nicotinic acetylcholine receptor at the neuromuscular junction). The antibodies are clinically important as disease markers and pathogenic mediators, but not a druggable molecule or receptor in the usual sense for drug discovery or pharmacological modulation.

Other names

Anti-acetylcholine receptor antibodyAnti-AChR antibodyAChR-Ab